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Abstract: Background:  The human eosinophil Charcot-Leyden Crystal (CLC) protein is a
member of the Galectin superfamily and is also known as Galectin-10 (Gal-10).
CLC/Gal-10 forms the distinctive hexagonal bipyramidal crystals considered hallmarks
of eosinophil participation in allergic responses and related inflammatory reactions;
however, the glycan-containing ligands of CLC/Gal-10, its cellular function(s), and its
role(s) in allergic diseases are unknown. 
Objective:  We sought to determine the binding partners of CLC/Gal-10 and elucidate
its role in eosinophil biology.
Methods:  Intracellular binding partners were determined by ligand blotting with
CLC/Gal-10, followed by co-immunoprecipitation and co-affinity purifications. The role
of CLC/Gal-10 in eosinophil function was determined by employing enzyme activity
assays, confocal microscopy, and shRNA knock-out of CLC/Gal-10 expression in
human CD34  +  cord blood hematopoietic progenitors differentiated to eosinophils.
Results:  CLC/Gal-10 interacts with both human eosinophil granule cationic
ribonucleases, eosinophil-derived neurotoxin (EDN, RNS2) and eosinophil cationic
protein (ECP, RNS3) , and with murine eosinophil-associated ribonucleases. The
interaction is independent of glycosylation and is not inhibitory toward
endoribonuclease activity. Activation of eosinophils with INF-γ induces the rapid co-
localization of CLC/Gal-10 with EDN/RNS2 and CD63. ShRNA knock-down of
CLC/Gal-10 in human cord blood-derived CD34  +  progenitor cells impairs eosinophil
granulogenesis.
Conclusions:  CLC/Gal-10 functions as a carrier for the sequestration and vesicular
transport of the potent eosinophil granule cationic ribonucleases during both
differentiation and degranulation, enabling their intracellular packaging and
extracellular functions in allergic inflammation.
Clinical Implications:  Understanding the crucial role of CLC/Gal-10 in eosinophil
differentiation/granulogenesis allows for further insights into potential therapeutic
targets to treat allergic diseases.
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Capsule summary: Charcot-Leyden protein/Galectin-10, a prominent eosinophil 29 
constituent associated with eosinophilic inflammation, functions as a binding partner for 30 
cationic ribonucleases and is required for eosinophil differentiation and granulogenesis. 31 
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ABSTRACT  42 
    43 
Background: The human eosinophil Charcot-Leyden Crystal (CLC) protein is a 44 
member of the Galectin superfamily and is also known as Galectin-10 (Gal-10). 45 
CLC/Gal-10 forms the distinctive hexagonal bipyramidal crystals considered hallmarks 46 
of eosinophil participation in allergic responses and related inflammatory reactions; 47 
however, the glycan-containing ligands of CLC/Gal-10, its cellular function(s), and its 48 
role(s) in allergic diseases are unknown.   49 
Objective: We sought to determine the binding partners of CLC/Gal-10 and elucidate 50 
its role in eosinophil biology. 51 
Methods: Intracellular binding partners were determined by ligand blotting with 52 
CLC/Gal-10, followed by co-immunoprecipitation and co-affinity purifications. The role of 53 
CLC/Gal-10 in eosinophil function was determined by employing enzyme activity 54 
assays, confocal microscopy, and shRNA knock-out of CLC/Gal-10 expression in 55 
human CD34+ cord blood hematopoietic progenitors differentiated to eosinophils. 56 
Results: CLC/Gal-10 interacts with both human eosinophil granule cationic 57 
ribonucleases, eosinophil-derived neurotoxin (EDN, RNS2) and eosinophil cationic 58 
protein (ECP, RNS3) , and with murine eosinophil-associated ribonucleases. The 59 
interaction is independent of glycosylation and is not inhibitory toward endoribonuclease 60 
activity. Activation of eosinophils with INF-γ induces the rapid co-localization of 61 
CLC/Gal-10 with EDN/RNS2 and CD63. ShRNA knock-down of CLC/Gal-10 in human 62 
cord blood-derived CD34+ progenitor cells impairs eosinophil granulogenesis. 63 
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Conclusions: CLC/Gal-10 functions as a carrier for the sequestration and vesicular 64 
transport of the potent eosinophil granule cationic ribonucleases during both 65 
differentiation and degranulation, enabling their intracellular packaging and extracellular 66 
functions in allergic inflammation. 67 
Clinical Implications: Understanding the crucial role of CLC/Gal-10 in eosinophil 68 
differentiation/granulogenesis allows for further insights into potential therapeutic targets 69 
to treat allergic diseases.  70 
 71 
72 
Grozdanovic et al - 5 
INTRODUCTION 73 
 74 
Charcot-Leyden crystals (CLC), first identified more than 150 years ago,1, 2  are found in 75 
a variety of tissues, body fluids and secretions as hallmarks of inflammation involving 76 
eosinophils and/or basophils in asthma, myeloid leukemias, allergic, parasitic, and other 77 
eosinophil-associated diseases and inflammatory reactions.3, 4 CLC protein 78 
autocrystallizes to form distinctive hexagonal bipyramidal crystals5, 6 and is the sole 79 
protein constituent of both native CLC formed in vivo7 and CLC prepared from disrupted 80 
eosinophils5, 6 and basophils8 in vitro. CLC is one of the most abundant eosinophil 81 
proteins comprising an estimated 7-10% of total cellular protein9 and was previously 82 
thought to be an eosinophil lysophospholipase,7, 9-11 but has since been reclassified as a 83 
member of the galectin superfamily of animal lectins,12 and it is hereafter referred to as 84 
CLC/Gal-10. However, unlike members of the galectin superfamily, many of which bind 85 
lactose and other -galactoside-containing oligosaccharides, and share 12 highly 86 
conserved residues that constitute the carbohydrate recognition domain (CRD),13-16 87 
CLC/Gal-10 has a putative carbohydrate recognition domain that contains only 7 out of 88 
the 12 conserved amino acid residues and does not bind ß-galactosides.17   89 
 90 
To date, the biologic activities and physiologic function(s) of CLC/Gal-10 in eosinophils 91 
(and basophils) with associated inflammatory responses in allergic diseases and host 92 
immune responses to parasitic helminths have remained indeterminate. Several studies 93 
have shown a direct association of CLC/Gal-10 levels with both airway and 94 
gastrointestinal eosinophilic inflammation. A strong correlation was observed between 95 
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CLC/Gal-10 levels and the percentage of eosinophils in the sputum of asthmatic 96 
patients.18 Sputum gene expression of CLC/Gal-10 was found to discriminate between 97 
inflammatory phenotypes in asthma and to predict response to inhaled corticosteroid.19 98 
Overexpression of CLC/Gal-10 mRNA was noted in the peripheral blood of patients with 99 
aspirin-induced asthma and mRNA levels of CLC/Gal-10 were also shown to be a 100 
marker of CRTH2 activation.20, 21 Genetic variation in CLC/Gal-10 was found to be 101 
associated with allergic rhinitis and patients with seasonal allergic rhinitis were found to 102 
have elevated levels of CLC/Gal-10 present in nasal lavage fluid during allergy 103 
season.22, 23 Analysis of protein expression patterns in gut biopsies of celiac disease 104 
patients found a positive correlation between CLC/Gal-10 levels and tissue damage, 105 
and a recent study showed that higher levels of CLC/Gal-10 mRNA distinguished 106 
children with eosinophilic esophagitis (EoE)  from control children.24, 25 A recent report 107 
by Persson et al., showed that human CLCs administered directly into mouse airways 108 
act as a type 2 adjuvant, mimicking many features of human asthma; the effects were 109 
readily reversible by CLC-dissolving anti-Gal-10 monoclonal antibodies, suggesting a 110 
possible therapeutic approach.26 Intriguingly, in addition to the considerable amounts 111 
present in eosinophils and basophils, CLC/Gal-10 is also expressed in human CD4+ 112 
CD25+ regulatory T cells, where it is necessary for the maintenance of 113 
immunosuppressive functions.27 As well, a recent study described a novel subset of 114 
CD16+ eosinophils that can suppress T-cells through a mechanism involving CLC/Gal-115 
10.28  116 
 117 
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Eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are among 118 
the major secreted effector proteins of human eosinophils29 present in the matrix of their 119 
large secondary (specific) granules. Both EDN and ECP have structural30-32 and 120 
catalytic30, 31, 33-36 residues typical of the ribonuclease A superfamily of proteins, and 121 
have been designated RNS2 (EDN) and RNS3 (ECP), with EDN having significantly 122 
greater ribonuclease activity (~100-fold) than ECP.37 Both EDN and ECP are highly 123 
glycosylated proteins variably decorated with N-linked and O-linked oligosaccharides, 124 
and for EDN, C-mannosylation is present as well.38 EDN and ECP are more than 60% 125 
homologous at the amino acid level35, 36 and their core polypeptides are ~15.5kD with 126 
multiple glycosylated isoforms (glycoforms) of molecular masses from 18-21kD and 127 
higher.39 These cationic ribonucleases likely function as anti-parasitic, anti-bacterial and 128 
anti-viral agents as part of both innate and adaptive host immune defense 129 
mechanisms.33, 34, 40-44 In addition, EDN and its murine ortholog eosinophil-associated 130 
RNase 2 (mEAR2), were reported to function as chemo-attractants for dendritic cells 131 
both in vitro and in vivo.40 These cationic ribonucleases are secreted by activated 132 
eosinophils in part by piecemeal degranulation (PMD),45 a process that involves 133 
vesicular transport from secondary granules to the extracellular space46 in the absence 134 
of classical granule exocytosis, but are also found in extracellular DNA traps.47, 48 135 
 136 
In the current study, we used ligand (far-Western) blotting to identify possible 137 
intracellular glycoprotein ligands for CLC/Gal-10 in the eosinophil, revealing the 138 
eosinophil granule cationic ribonucleases (EDN/RNS2 and ECP/RNS3) as major 139 
binding partners for this unusual galectin. We demonstrate that CLC/Gal-10 does not 140 
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inhibit their ribonuclease activity and show the intracellular movement and co-141 
localization of CLC/Gal-10 with EDN and CD63 during eosinophil activation. Finally, we 142 
demonstrate through shRNA knock-down of CLC/Gal-10 in human CD34+ 143 
hematopoietic progenitors, a functional role and requirement for this galectin in 144 
granulogenesis during IL-5-driven eosinophil differentiation.  145 
 146 
 147 
MATERIALS AND METHODS 148 
 149 
Purification of human blood eosinophils 150 
Blood eosinophils were obtained from normal, non-allergic, non-asthmatic subjects with 151 
informed donor consent according to IRB approved protocols at the University of Illinois 152 
at Chicago. The purification of eosinophils by magnetic-activated cell sorting (Miltenyi 153 
Biotec AutoMACS) was performed as previously described.15 154 
 155 
Cell lines and culture 156 
The AML14.3D10 eosinophil-differentiated myelocyte cell line49 was kindly provided by 157 
Drs. Cassandra Paul and Michael Baumann (VA Medical Center and Wright State 158 
University, Dayton, OH).  The AML14.3D10 myelocyte line displays many of the 159 
characteristics of mature peripheral blood eosinophils, including constitutive expression 160 
of the major protein mediators of the eosinophil such as the granule cationic proteins 161 
major basic protein-1 (MBP-1), eosinophil peroxidase (EPX), EDN and ECP, and 162 
CLC/Gal-10.50-52 AML14.3D10 eosinophils express CLC/Gal-10 protein in amounts 163 
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comparable to that of peripheral blood eosinophils.15  Cells were maintained in RPMI 164 
1640 medium supplemented with 2mM L-glutamine, 50 µM -mercaptoethanol, 1 mM 165 
sodium pyruvate and 8% fetal bovine serum. Purified human CD34+ cord blood-derived 166 
hematopoeitic progenitor cells were purchased from AllCells (Emeryville, CA) and 167 
cultured in IMDM media containing 10% FBS, 2 mM L-glutamine, 50 µM β-168 
mercaptoethanol, and 1% Penicillin-Streptomycin. The media was supplemented with 169 
100 ng/mL of FMS-like tyrosine kinase-3 (FLT-3) ligand, stem cell factor (SCF), and 170 
Thrombopoietin (TPO) for the first 48h of culture. 171 
 172 
Purification of eosinophil granule cationic proteins  173 
Purified human EDN, ECP, and MBP-1 were generous gifts from Drs. Gerald Gleich 174 
and Hirohito Kita (Mayo Clinic, Rochester, MN). The purification procedures for the 175 
human eosinophil granule cationic proteins have been described in detail previously.39, 176 
53  Purified murine eosinophil-associated ribonucleases (EARS)33, 54-56 were a generous 177 
gift from Dr. James J. Lee (Mayo Clinic, Scottsdale, AZ). 178 
 179 
Ligand (far-western) blotting with CLC/Gal-10 protein probe   180 
Cell lysates or purified eosinophil granule cationic proteins were resolved by SDS-181 
PAGE and transferred onto PVDF membranes. After blocking with 5% non-fat dry milk, 182 
the membranes were incubated for one hour with 10 g/mL of pure crystal-derived 183 
CLC/Gal-10 protein in 100mM Tris-HCL buffer (pH 7.5). The membranes were further 184 
probed with affinity-purified rabbit anti-CLC/Gal-10 antibody. The crystal-derived 185 
CLC/Gal-10 used for ligand blotting was prepared according to published protocols.6, 15, 186 
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57 Protein bands identified by binding to CLC/Gal-10 were excised from the membrane 187 
and subjected to trypsin digestion, followed by MALDI-TOF/MS analysis on an Applied 188 
Biosystems Voyager DE-STR instrument. 189 
 190 
Enzymatic Deglycosylation and PAS staining 191 
Blood eosinophil lysates or purified eosinophil granule cationic proteins were subjected 192 
to digestion with PNGase F (New England Biolabs, Ipswich, MA),  Sialidase A, O-193 
Glycanase, β-(1-4) Galactosidase, and β-N-Acetylglucosaminidase (Prozyme, Hayward, 194 
CA)  according to the manufacturer’s protocols. Staining for glycoproteins was 195 
performed using a PAS Glycoprotein Detection Kit™ (Sigma-Aldrich, St. Louis, MO). 196 
 197 
Antibodies to native CLC/Gal-10, EDN/ECP, and MBP-1  198 
Affinity purification and preparation of rabbit polyclonal anti-CLC/Gal-10 and rabbit 199 
polyclonal anti-EDN/ECP was previously described in detail elsewhere and in the Online 200 
Repository Materials.15, 53 An anti-EDN monoclonal antibody (clone 167-6C5) that does 201 
not recognize ECP or any other eosinophil granule cationic protein, and an MBP-1-202 
specific monoclonal antibody were provided by Drs. Gerald Gleich and Hirohito Kita 203 
(Mayo Clinic, Rochester, MN).   204 
 205 
Co-immunoprecipitation, affinity co-purification and confocal microscopy 206 
Co-immunoprecipitation and affinity co-purification of CLC/Gal-10 and EDN and 207 
confocal immunofluorescence microscopy to determine colocalization of CLC/GAL-10 208 
with EDN and CD63 are described in detail in the Online Repository Materials. 209 
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 210 
Ribonuclease enzyme activity assay 211 
The assay was performed using a cleavable fluoro-labeled substrate (Ambion, Austin, 212 
TX) and is further described in the Online Repository Materials.  213 
 214 
Knock-down of CLC/Gal-10 in cord blood CD34+ progenitor cells 215 
CD34+ cells were transduced with MISSION lentiviral shRNA transduction particles 216 
(Sigma- Aldrich, St. Louis, MO) at an MOI of 5 for 20 hours. Cells were collected, the 217 
viruses washed away, and the media supplemented with 100 nM IL-3 and IL-5 (R&D 218 
Systems, Minneapolis, MN) for the remainder of the experiment to promote 219 
differentiation of the eosinophil lineage. Cells were maintained at a concentration of 0.3-220 
1.0 x 106 cell/mL for 14 or 21 days. Six days after the virus particles were removed, 2 221 
µg/mL Puromycin (Sigma- Aldrich, St. Louis, MO) was added to the media in order to 222 
select for cells transduced with the shRNA lentiviral particles. Cells were stained using 223 
Fast Green/ Neutral Red and May-Grünwald Giemsa (Sigma- Aldrich, St. Louis, MO) 224 
according to the manufacturer’s protocol. Cell morphology on cytocentrifuge slides 225 
(Shandon Cytospin II, Thermo Fisher Scientific, Waltham, MA) was evaluated by 226 
differential counts on sequential 40X high power fields, counting at least 200 cells/slide. 227 
 228 
Detection of granule proteins in CD34+ progenitor cell-derived eosinophils 229 
CLC/Gal-10, EDN, ECP, EPX and MBP-1 were detected in cell lysates 21 days after 230 
transduction of cells with either non-target control or CLC/Gal-10 specific shRNAs. 231 
Granule protein levels were detected using double-antibody sandwich ELISAs as 232 
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previously described.58 EPX was detected using a commercially available ELISA kit 233 
(Lifespan Bioscience Inc, Seattle, WA). 234 
 235 
Degranulation of  CD34+ progenitor cell-derived eosinophils 236 
Degranulation of CD34+ progenitor cell-derived in vitro differentiated eosinophils was 237 
performed by incubating 0.5 x 105 cells/well with 0, 2, 4, and 6 µM PAF (Platelet-238 
activating factor (PAFC16) (Sigma-Aldrich, St. Louis, MO) in cell culture plates previously 239 
coated with 3% human serum albumin in PBS. Cells were incubated at 37°C and 5% 240 
CO2 for 4h and protein concentrations of EDN and EPX were measured in cell 241 




Identification of a 21kD protein in blood eosinophils that binds CLC/Gal-10 246 
In order to identify a potential intracellular ligand(s) for CLC/Gal-10, we performed 247 
CLC/Gal-10 protein ligand blotting (far-western blotting) of blood eosinophil whole cell 248 
lysates before or after enzymatic cleavage of N-linked glycans by PNGase F (Fig. 1A). 249 
Following incubation of cell lysates with crystal-derived CLC/Gal-10 protein, interacting 250 
protein bands were detected by a highly specific affinity-purified anti-CLC/Gal-10 251 
antibody.59 In addition to detecting the expected endogenous CLC/Gal-10 present in 252 
blood eosinophils, this approach also identified a 21kD protein that interacted with 253 
CLC/Gal-10 (Fig. 1A). The detected 21kD protein still bound CLC/GAL-10 after being 254 
reduced to 18kD following PNGase F digestion(Fig. 1B). The 18kD band became 255 
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visible only after carefully removing the membrane section containing monomeric 256 
CLC/Gal-10 following membrane transfer during western blotting. Importantly, MALDI-257 
TOF/MS analysis identified the 21kD band as the two eosinophil granule cationic 258 
ribonucleases, EDN (RNS2) and ECP (RNS3). The 18kD band that appears after 259 
enzymatic cleavage of N-linked glycans was also confirmed by MALDI-TOF/MS to be 260 
comprised of EDN and ECP, suggesting them as possible intracellular ligands for this 261 
eosinophil galectin. 262 
 263 
EDN/ECP co-purify and co-immunoprecipitate with CLC/Gal-10 264 
The finding of a CLC/Gal-10-eosinophil ribonuclease interaction by ligand blotting 265 
prompted us to determine if EDN and/or ECP co-purify or co-immunoprecipitate with 266 
CLC/Gal-10 from eosinophil lysates.  EDN co-purified with CLC/gal-10 from both 267 
AML14.3D10 eosinophilic myelocytes and blood eosinophils on a column of affinity 268 
purified anti-CLC/Gal-10 antibody15 (Fig. 1C). MBP-1, the most cationic (pI=11.3) 269 
granule protein of the eosinophil,60  was used as a specificity control (Fig. 1C, bottom 270 
panel). We next performed cross-immunoprecipitations of AML14.3D10 eosinophil 271 
lysates using either anti-CLC/Gal-10 or EDN-specific mouse monoclonal antibody. Both 272 
proteins co-immunoprecipitated with one another as detected by Western blotting (Fig. 273 
1D), and the EDN that co-immunoprecipitated was ~15kD, comparable in size to the 274 
non-glycosylated core polypeptide.  275 
 276 
CLC/Gal-10 binds to purified eosinophil ribonucleases 277 
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To confirm the binding and specificity of CLC/Gal-10 for EDN and ECP, we repeated the 278 
ligand blotting procedure using purified human eosinophil granule-derived native EDN 279 
and ECP proteins, murine eosinophil-associated ribonucleases (EARS), and MBP-1 280 
(Fig. 2A). CLC/Gal-10 bound to EDN, to the mouse EARS (a mixture containing EARS-281 
1, -2, -3, -4, -6, -7 and –8), and to some, but not all glycoforms of ECP. In contrast, 282 
CLC/Gal-10 did not bind MBP-1, indicating that the interaction between CLC/Gal-10 and 283 
EDN/ECP/EARS was not due to a simple non-specific charge interaction between the 284 
slightly acidic CLC/Gal-10 (pI  5.1-5.7) and the granule cationic proteins.  285 
 286 
Oligosaccharides are not required for the CLC/Gal-10 – ribonuclease interactions 287 
To further characterize the mechanism of interaction between CLC/Gal-10 and the 288 
eosinophil ribonucleases in terms of galectin-carbohydrate versus protein-protein 289 
interactions, we used purified human EDN and ECP, and mouse EARS for CLC/Gal-10 290 
ligand blotting in combination with PNGase F digestion to remove their N-linked sugars. 291 
The cleavage of N-linked sugars did not significantly diminish their recognition by 292 
CLC/Gal-10 (Fig. 2A).  Despite efficient digestion with PNGase F (visible by the size/ 293 
mobility shift of the digested bands), both EDN, ECP and the mouse EARS remained 294 
PAS positive.  This result is consistent with previous findings that the eosinophil 295 
ribonucleases also contain O-linked sugars,39 and that EDN is also C-mannosylated.38 296 
We extended our studies by performing CLC/Gal-10 ligand blotting on EDN that was 297 
digested with PNGase F, followed by sialidase A (to remove sialic acid residues) and 298 
finally a series of exoglycosidases (to remove O-linked sugars) (Fig. 2B). Results 299 
showed a non-diminished CLC/Gal-10-EDN interaction, again suggesting that the 300 
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interaction is independent of glycan binding. However, due to O-glycans being 301 
notoriously difficult to remove, EDN was still positive for PAS staining and we did not 302 
see the native EDN fully reduced in size to that of the non-glycosylated rEDN. In order 303 
to fully clarify whether glycans are necessary for CLC/Gal-10 binding to EDN, we 304 
directly compared the ability of eosinophil-derived native glycosylated EDN and 305 
recombinant bacterially-expressed non-glycosylated EDN to bind CLC/Gal-10 (Fig. 2C). 306 
Increasing amounts of either recombinant or native EDN shows an equal affinity of 307 
CLC/Gal-10 for either of these proteins in a dose-response fashion.  This relationship 308 
further demonstrates that the CLC/Gal-10-EDN interaction is not oligosaccharide-309 
dependent and that oligosaccharides do not change the affinity of CLC/Gal-10 for EDN. 310 
In addition, we employed molecular modelling techniques to identify possible amino 311 
acids involved in protein-protein interactions between EDN and CLC/Gal-10 312 
(Supplementary Figures S1-S4). A surface patch of ~39 Å3 with hydrophobic residues 313 
and electro-positive charge was identified on CLC/Gal-10 and found to be 314 
complementary to a similar patch (also ~39 Å3) on EDN. Residues comprising these two 315 
hydrophobic surface patches are predicted to be involved in CLC/Gal-10 and EDN 316 
protein-protein interactions. Of note, out of the 26 residues identified (see 317 
Supplementary materials), only one residue (H53) is located in the putative 318 
carbohydrate recognition domain (CRD) of CLC/Gal-10.17  319 
 320 
CLC/Gal-10 does not bind to any known mammalian glycans 321 
In order to identify specific glycan ligands for CLC/Gal-10, we performed glycan 322 
microarray screening in collaboration with the Consortium for Functional Glycomics 323 
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(CFG). The CFG's Protein-Glycan Interaction Core (formerly Core H) probed the CFG 324 
mammalian glycan array with crystal-derived CLC/Gal-10, bacterially expressed 325 
recombinant CLC/Gal-10, and a recombinant 5-amino acid mutant of CLC/Gal-10 326 
(Q55N, C57R, R61T, Q75E, E77R) engineered to have a consensus galectin CRD.  327 
Several detection strategies were employed; however, neither native, recombinant wild 328 
type, nor the mutant rCLC/Gal-10 showed any significant binding to the glycan ligands 329 
displayed on the microarrays (Table S1). The mammalian glycan array data is 330 
discussed in detail in the Online Repository materials. 331 
 332 
CLC/Gal-10 does not inhibit EDN ribonuclease activity 333 
To determine whether CLC/Gal-10 might function as an EDN/ECP RNase activity 334 
inhibitor during their mobilization and secretion during PMD by the activated eosinophil,  335 
we performed RNase activity assays (Fig. 3).  Crystal-derived CLC/Gal-10 protein 336 
neither inhibited nor enhanced the ribonuclease activity of a constant amount of EDN 337 
(80 pg) regardless of the amount of CLC/Gal-10 protein added, whereas placental 338 
ribonuclease inhibitor blocked the RNase activity of EDN in a dose-dependent fashion 339 
(Fig. 3A).  Likewise, there was no difference in the RNase activity of increasing 340 
amounts of EDN assayed in the presence of a fixed amount of CLC/Gal-10 (400 pg) 341 
(Fig. 3B), whereas a constant amount of RNase inhibitor blocked the RNase activity of 342 
all concentrations of EDN. 343 
 344 
CLC/Gal-10 co-localizes with EDN and CD63 in IFN-γ activated eosinophils 345 
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In freshly purified unstimulated blood eosinophils, CLC/Gal-10 was localized principally 346 
in the cytosolic compartment, mainly in the agranular regions immediately beneath the 347 
plasma membrane, while EDN was present within the eosinophil secondary granule 348 
compartment throughout the cell and was not co-localized with CLC/Gal-10 (Fig. 4A, 10 349 
min and 30 min controls). In contrast, when eosinophils were activated with IFN-γ, a 350 
potent eosinophil secretagogue that induces the vesicular transport and secretion of 351 
EDN and ECP by the process of PMD,46, 61 much of the CLC/Gal-10 became co-352 
localized with EDN within the cytosolic compartment (Fig. 4A and Supplementary 353 
Figure S7A).  The CLC/Gal-10-EDN co-localization reached a peak ~30 minutes after 354 
stimulation with IFN-γ, with bright cytosolic “pockets” of the co-localized proteins 355 
apparent in agranular regions of the cell distinct from the secondary granules. 356 
Approximately 60 min after eosinophil activation with IFN-γ, the staining pattern for 357 
CLC/Gal-10 began to approximate its original cytosolic localization (not shown). To 358 
determine whether eosinophil activation induces the association of CLC/Gal-10 with the 359 
tetraspanin CD63, a transmembrane protein of eosinophil secondary granules62 360 
associated with vesicular transport and mediator release during eosinophil PMD,63 361 
normal blood eosinophils were activated with IFN-γ as performed above (Fig. 4B).  362 
Within 10 minutes of activation, CLC/Gal-10 and CD63 showed a pattern of co-363 
localization within a discrete subset of secondary granules within the cytosol (Fig. 4B, 364 
10 and 30 min.), with continued co-localization evident after 60 min (Supplementary 365 
Figure S7B). 366 
 367 
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shRNA knock-down of CLC/Gal-10 in eosinophil progenitors impairs eosinophil 368 
differentiation/granulogenesis 369 
To further determine the role of CLC/Gal-10 in eosinophil biology, we employed 370 
targeted shRNA knock-down of CLC/Gal-10 in purified human CD34+ cord blood-371 
derived progenitor cells. These hematopoietic progenitors were then driven to 372 
differentiate to the eosinophil lineage with IL-5, resulting in mature (or nearly mature) 373 
eosinophils that do not express CLC/Gal-10. Immunofluorescence staining of cells at 374 
day 14 showed an almost complete loss of CLC/Gal-10 expression in cells treated with 375 
CLC/Gal-10 specific shRNA lentiviral particles (Fig. 5A, top panel). Fast Green/Neutral 376 
red staining of cells showed characteristic features of eosinophils, including red nuclei, 377 
pink cytoplasm and green granules; confirming that the cells were successfully 378 
differentiated toward the eosinophil lineage (Fig. 5A). After 14 days, the CLC/Gal-10 379 
knock-down cells showed a significant reduction in the number of Fast Green stained 380 
secondary granules, and cells stained on day 21 showed increasing differences in 381 
cellular morphology as compared to control cells (Fig. 5A, bottom panel). Specifically, 382 
the size of the granules in the CLC/Gal-10 knock-down cells was substantially larger 383 
than those of either the non-transduced or non-target control shRNA cells. In addition, 384 
many of these granules did not stain with Fast Green at all, suggesting that they do not 385 
contain any secondary granule proteins and represent only large empty containers 386 
formed by fusion of empty granules (Fig. 5B).  387 
 388 
The CLC/Gal-10 knock-down cells displayed an ~42% decrease in the average number 389 
of secondary granules as compared to the non-target shRNA transduced cells (Fig. 390 
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6A), mostly manifested by a dramatic increase of cells with no detectable granules at 391 
all, and a strikingly smaller number of cells with more than 15 granules (Fig. 6B). Cells 392 
transfected with CLC/Gal-10 shRNA also presented as a non-proliferating phenotype. In 393 
these cells, no cell proliferation was observed for the duration of the experiment, in 394 
contrast to non-transfected (untreated) cells and non-target shRNA transfected control 395 
cells that both increased ~10-fold in numbers during the same time span (Fig. 6C). Cell 396 
viability remained high (≥ 90%) in all cell groups for the entire duration of the 397 
experiment. Analysis of cell lysates 14 days after CLC/Gal-10 knock-down 398 
demonstrated the expected lack of CLC/Gal-10 expression both by western blotting 399 
(Online Repository Figure S6) and ELISA (Fig. 6D). Interestingly, CLC/Gal-10 knock-400 
down also caused a significant decrease in detected MBP-1 levels, but no change in 401 
EDN, ECP or EPX expression (Fig. 6D).  402 
To determine the effect of CLC/Gal-10 knock-down on degranulation of in vitro-403 
differentiated eosinophils, we incubated the cells with 2, 4, and 6µM Platelet Activating 404 
Factor (PAF) (a known eosinophil secretagogue) and measured  levels of EPX and 405 
EDN in cell supernatants following 4h of PAF stimulation (Fig. 6E and 6F). The PAF-406 
activated CLC-deficient eosinophils exhibited dose-dependent degranulation with 407 
secretion of both EPX and EDN. The secretion of EPX by CLC-deficient eosinophils 408 
was not significantly different from that observed for untreated cells or non-target 409 
shRNA controls (Fig. 6F); however, the amount of secreted EDN was significantly 410 
higher in CLC-deficient eosinophils (Fig 6E). Of interest, the CLC-deficient eosinophils 411 
“leaked” EDN into the culture media even in the absence of the PAF secretagogue (Fig. 412 
6E at 0µM PAF). 413 
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 414 
DISCUSSION 415 
Although clearly a member of the galectin superfamily, CLC/Gal-10 possesses a 416 
modified CRD that does not specifically bind lactose or other galactosamine-containing 417 
glycans. The oligosaccharides, if any, that bind to the CLC/Gal-10 CRD remain 418 
unknown, and in our current study we present data from glycan microarray probes 419 
demonstrating that CLC/Gal-10 does not bind any known mammalian glycan structures, 420 
thus leaving the function(s) of CLC protein as a galectin in eosinophil (and basophil) 421 
biology unresolved. One of our earlier structural studies showed binding of mannose to 422 
the CLC/Gal-10 carbohydrate recognition domain in the crystal, but in an unusual, non-423 
standard β-half chair conformation.64 Subsequent studies demonstrated that CLC/Gal-424 
10 can weakly (non-specifically) bind to carbohydrate under several conditions, like in 425 
its monomeric state.65, 66 In addition, recent findings indicate that Gal-10 dimerizes with 426 
a novel global shape that is different from that of other prototype galectins (e.g., Gal-1, -427 
2 and -7) and may essentially inhibit disaccharide binding.65, 67 The lack of binding to ß-428 
galactosides was also recently demonstrated for one other galectin family member, 429 
Galectin-13, which exhibits approximately 54% amino acid identity with CLC/Gal-10.68 430 
 431 
Our results further show that CLC/Gal-10 interacts with the glycosylated human 432 
eosinophil granule cationic ribonucleases, EDN (RNS2) and ECP (RNS3), but that this 433 
interaction is not dependent on binding via N- or O-linked sugars, and occurs even with 434 
bacterially expressed recombinant EDN devoid of any glycosylation. Of interest, 435 
CLC/Gal-10 also binds avidly to the large family of murine eosinophil-associated-436 
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ribonucleases (EARS), despite the lack of a CLC/Gal-10 ortholog in the mouse genome. 437 
This might simply reflect similarities of sequence and/or structure between EDN/ECP 438 
and the murine EARS or suggests the existence of an as yet unidentified CLC/Gal-10 439 
paralog in the mouse.  440 
 441 
We demonstrate that CLC/Gal-10 does not function as an inhibitor of the granule 442 
cationic endoribonucleases, and instead find that IFN-γ activation of blood eosinophils 443 
induces rapid intracellular movement and co-localization of CLC/Gal-10 with EDN and 444 
CD63.  A number of studies have implicated the tetraspanin CD63 in the process of 445 
agonist-induced eosinophil secretion as part of the selective mobilization of eosinophil-446 
expressed cytokines and granule cationic proteins via vesicular transport from 447 
eosinophil secondary granules.61, 63, 69, 70 As a result, CD63 has been proposed as a 448 
marker of PMD in eosinophils.45 Our finding that CLC/Gal-10 rapidly becomes 449 
associated with both CD63-positive secondary granules and EDN during the process of 450 
IFN-γ -induced eosinophil activation is indicative of a possible role for CLC/Gal-10 in the 451 
vesicular transport of the cationic ribonucleases. Extended studies in actively secreting 452 
eosinophils on the co-localization of CLC/Gal-10 with components of the vesicular 453 
transport pathway expressed by eosinophils (including VAMP-2, VAMP-7, VAMP-8, 454 
syntaxin-4, and SNAP-23)71-73 will further elucidate the role of CLC/Gal-10 in the 455 
process of PMD.   456 
 457 
The absence of a murine ortholog or paralog of CLC/Gal-10  knockout studies in the 458 
mouse to address its functions in eosinophil biology and/or roles in eosinophil-459 
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associated inflammatory responses. However, we extended the current studies by 460 
utilizing lentiviral shRNA to knock-down CLC/Gal-10 in cord blood CD34-positive 461 
hematopoietic progenitors driven to differentiate into eosinophils.  While knockdown of 462 
CLC/Gal-10 did not inhibit eosinophil progenitor proliferation, granulogenesis was 463 
significantly impaired, with decreased formation of Fast Green positive secondary 464 
granules.  Knockdown cells also contained increased numbers of large empty granule 465 
containers and very large empty granules, suggesting fusion of empty granule 466 
containers in CLC/Gal-10 deficient eosinophils. These findings indicate a role for 467 
CLC/Gal-10 in granulogenesis during eosinophil differentiation, and are consistent with 468 
our hypothesis that CLC/Gal-10 is involved in vesicular transport of the ribonucleases 469 
during both PMD and eosinophilopoiesis.  We would expect CLC/Gal-10 to function in 470 
this role throughout differentiation, from granulogenesis until mediator secretion from 471 
the mature cell. Unlike our findings for CLC/Gal-10, previous reports on the 472 
consequences of eosinophil granule protein gene knockout demonstrated that the only 473 
baseline consequence of losing either MBP-1 or EPX in single gene knockout mice is 474 
the generation of peripheral blood eosinophils devoid of the respective secondary 475 
granule protein74, 75 or with a relative reduction in granule outer matrix volume.76 In 476 
contrast, MBP-1-/-/EPX-/- double knockout mice were viable but had significantly fewer 477 
circulating peripheral blood eosinophils, a consequence of concomitant loss of 478 
eosinophil lineage-committed progenitors in the marrow due to targeted disruption of 479 
eosinophilopoiesis. The authors hypothesized that granule protein gene expression 480 
and/or granule formation is a checkpoint for survival of developing EoPs (eosinophil 481 
progenitors).77 However, an alternative explanation for the dysfunctional granulogenesis 482 
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in MBP-1-/-/ EPX-/- double knockout mice could also involve the aberrant intracellular 483 
release of a toxicant, the mouse eosinophil-associated ribonucleases (EARs), which are 484 
capable of rapidly degrading intracellular RNA, thus leading to the observed cell-485 
autonomous defect.78 Therefore, we hypothesize that CLC/Gal-10 may function as a 486 
carrier (chaperone) for the sequestration and vesicular transport of these potent 487 
ribonucleases and cationic toxins during eosinophil activation and secretion by PMD. In 488 
support of this hypothesis, beside data presented in this study, are a number of other 489 
considerations: the abundance of CLC/Gal-10 in the eosinophil (~7-10% of total cellular 490 
protein), the very early expression of CLC/Gal-10 mRNA during eosinophil 491 
differentiation, and the status of CLC/Gal-10 as the second most abundant mRNA next 492 
to MBP-1 in the developing eosinophil progenitor.79 In addition, CLC/Gal-10 was found 493 
not to be actively secreted to the extracellular space in basophils,80 but instead 494 
becomes rapidly associated with small cytosolic vesicles involved in granule protein and 495 
cytokine transport and secretion in the process of eosinophil PMD, with re-cycling of 496 
CLC/Gal-10 during basophil recovery from stimulation with physiologically relevant 497 
agonists.69, 70, 76, 77, 80 Ultrastructural TEM studies showed changing distributions of 498 
CLC/Gal-10 in human basophils upon activation, documenting the capability of 499 
basophils to undergo complex release and recovery reactions that may be pertinent to 500 
the functions of CLC protein.81 A similar recycling process in human eosinophils is 501 
supported by our finding that CLC/Gal-10 returns to its original cytosolic localization 60 502 
min after IFN-γ activation. However, there is also evidence that CLC/Gal-10 may be 503 
secreted during eosinophil differentiation or during eosinophil-associated inflammatory 504 
reactions.3, 6, 82-85 505 
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 506 
The effect of CLC/Gal-10 deficiency on the activation and degranulation of in vitro 507 
differentiated eosinophils was assessed by measuring the secretion of EDN and EPX 508 
following stimulation of the cells with PAF. Platelet activating factor is a well-studied 509 
eosinophil secretagogue shown to induce eosinophil degranulation via both exocytosis73 510 
and piecemeal degranulation,86 although the exact mechanism of its action on 511 
eosinophils is unknown.87 Stimulation with PAF resulted in a dose-dependent secretion 512 
of EPX and EDN, suggesting that CLC/Gal-10 deficient eosinophils do not have a 513 
generalized defect in degranulation. However, secretion of EDN by CLC/Gal-10 514 
deficient eosinophils was significantly higher than that of controls, and EDN was found 515 
to “leak” into the media in the absence of a secretagogue, suggesting a deficiency in 516 
EDN packaging and/or transport not evident for other secondary granule constituents 517 
such as EPX. 518 
 519 
Of interest, analysis of CLC/Gal-10 ShRNA knock-down cell lysates showed decreased 520 
levels of MBP-1, but not EDN, ECP or EPX.  It is possible that EDN/ECP translation is 521 
unaffected, while the targeting of these proteins to the granules through the golgi during 522 
differentiation is defective. Although the presence of cationic ribonucleases in 523 
eosinophils with impaired granulogenesis would imply cellular cytotoxicity, this was not 524 
the case in our current study. Possible reasons could include an altered form of 525 
subcellular localization or even aggregation of these ribonucleases. Impaired 526 
granulogenesis could also drive expression of modified/inactive EDN and ECP. Unlike 527 
the other eosinophil-derived granule proteins (including MBP-1), EDN is a poor cationic 528 
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toxin with limited toxicity for helminth parasites and mammalian cells at high 529 
concentrations. As a ribonuclease, it is considerably more effective against single-530 
stranded RNA viruses.88 Native ECP purified from leukocytes shows considerable 531 
molecular heterogeneity, from multiple glycosylated isoforms to the non-glycosylated 532 
native protein; these glycoforms vary considerably in cytotoxic activity toward 533 
mammalian cells.88, 89 Notably, we observed complete cessation of cell proliferation 534 
upon knock-down of CLC/Gal-10, an effect not seen in controls transfected with non-535 
target shRNA, indicating CLC/Gal-10-deficiency does not lead to cytotoxicity, but 536 
significantly impairs packaging of both the ribonucleases and other granule cationic 537 
proteins during eosinophil development. The defective granulogenesis observed in 538 
developing CLC/Gal-10-deficient eosinophils is also likely responsible for decreased 539 
gene expression and/or protein synthesis of MBP-1, but further studies are needed to 540 
reach more definitive conclusions. 541 
 542 
Recognizing the crucial role of CLC/Gal-10 in eosinophil granulogenesis, and the 543 
identification of eosinophil ribonucleases as intracellular ligands for CLC/Gal-10, opens 544 
a window to understanding the physiologic roles of this unique member of the galectin 545 
family in eosinophil (and basophil) biology, and its potential functions in innate and 546 
adaptive immunity. 547 
548 
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FIGURE LEGENDS 841 
Figure 1. CLC/Gal-10 interacts with eosinophil granule cationic ribonucleases. (A, 842 
B) CLC/Gal-10 was used as a probe to “ligand blot” blood eosinophil lysate, followed by 843 
detection with anti-CLC/Gal-10 antibody. CLC/Gal-10 binds to an ~21kD band in blood 844 
eosinophil lysate that is reduced to ~18 kD upon digestion of the lysates with PNGase 845 
F. (C) EDN co-purifies with CLC/Gal-10 from lysates of AML14.3D10 eosinophils or 846 
purified blood eosinophils. Samples affinity purified over an anti-CLC/Gal-10 antibody 847 
column were blotted with either anti-CLC/Gal-10 or anti-EDN/ECP (cross-reactive) 848 
antibodies. Purified MBP-1 and anti-MBP-1 antibodies were used as a control. (D) EDN 849 
is co-immunoprecipitated by anti-CLC/Gal-l0 antibody (left panel) and CLC/Gal-10 is co-850 
immunoprecipitated by anti-EDN antibody (right panel) from AML14.3D10 eosinophil 851 
lysate. The initial AML14.3D10 lysate (input) was included as a positive control. The 852 
immunoprecipitations were performed using rabbit non-immune (NI) IgG, anti-CLC/Gal-853 
10, or anti-EDN antibodies.  854 
 855 
Figure 2. Interaction of CLC/Gal-10 with the cationic endoribonucleases is not 856 
glycan-dependent. (A) Purified human (EDN, ECP, MBP-1) and murine (EARS) 857 
eosinophil granule proteins (2.5 µg/ each) bind CLC/Gal-10 in ligand blot, with or without 858 
prior PNGase digestion. Electrotransferred samples were detected by Coomassie Blue 859 
stain (top), anti-CLC/Gal-10 antibody (middle) or glycoprotein stain (PAS) (bottom). (B) 860 
Native (glycosylated) human EDN binds CLC/Gal-10 even after being subjected to 861 
sequential digestions with PNGase F, Sialidase A, O-Glycanase, β-(1-4) Galactosidase, 862 
and β-N-Acetylglucosaminidase. The samples were stained for protein by Coomassie 863 
Blue (top), ligand blotted using CLC/Gal-10 followed by anti-CLC/Gal-10 (middle), and 864 
glycoprotein by PAS (bottom).  865 
(C) Purified native EDN and recombinant EDN have similar affinities for CLC/Gal-10 866 
binding, as demonstrated by ligand blotting increasing amounts of EDN (1, 2, 4, and 8 867 
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µg)  with crystal-derived CLC/Gal-10, followed by detection of bound CLC/Gal-10 with 868 
anti-CLC/Gal-10 antibodies.  Bacterially expressed non-glycosylated rEDN was included 869 
for comparison.  870 
 871 
Figure 3. CLC/Gal-10 does not inhibit the ribonuclease activity of EDN. (A) 80 pg of 872 
purified native EDN was analyzed for RNase activity in the absence or presence of 873 
increasing amounts of CLC/Gal-10 protein, or placental RNase inhibitor. The relative 874 
fluorescence units reflect the amount of fluorescence emitted by the cleavable 875 
fluorescent-labeled RNase substrate. The amount of crystal-derived CLC/Gal-10 protein 876 
ranged from 0 to 1600 pg, and human placental RNase inhibitor ranged from 0 to 5 877 
units. (B) Increasing amounts of EDN were incubated with a constant amount of either 878 
CLC/Gal-10 (400 pg) or placental RNase inhibitor (5 units). Results are representative 879 
of 3 independent experiments with three different preparations of CLC/Gal-10 protein 880 
purified by crystallization from blood eosinophils. ns = not significant 881 
 882 
Figure 4.  Activation of blood eosinophils with IFN-γ induces the intracellular co-883 
localization of CLC/Gal-10 with EDN and CD63. 884 
(A) Representative confocal images of blood eosinophils cultured without (control) or 885 
with IFN-γ (500 U/ml) for periods of 10 to 30 min. Upon activation with IFN-γ, the 886 
merged images clearly display yellow regions indicative of co-localization of CLC/Gal-10 887 
and EDN. Co-localization reaches maximum levels 30 min after activation and 888 
dissipates after 60 min (not shown). (B) Purified eosinophils stimulated with IFN-γ  (500 889 
U/ml) for periods of 2, 10, 30, or 60 minutes show CLC/Gal-10 and CD63 co-localization 890 
at discrete punctate sites in the cytosol consistent in size with eosinophil secondary 891 
granules. Maximum colocalization is visible 30 min after activation. DIC shows the 892 
appearance of typical eosinophil secondary granules in the cytosol. Results include 893 
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representative images from 4 independent experiments. Arrows highlight pockets of co-894 
localization. White size bars in lower right corner indicate 5µm. 895 
 896 
Figure 5. shRNA knock-down of CLC/Gal-10 in cord-blood derived eosinophil 897 
progenitor cells leads to impaired eosinophil differentiation/ granulogenesis. (A) 898 
Purified human CD34+ cord blood-derived progenitor cells were transduced with 899 
specific CLC/Gal-10 shRNA or Non-Target control shRNA and then differentiated 900 
toward the eosinophil lineage with IL-5. Immunofluorescence staining of cells at day 14 901 
shows an almost complete loss of CLC/Gal-10 expression in cells treated with CLC/Gal-902 
10 specific shRNA (Fig. 5A, top panel). Fast Green/Neutral Red staining of cells shows 903 
characteristic features of mature eosinophils, including red nuclei, pink cytoplasm and 904 
turquoise green granules, confirming that the cells were successfully differentiated 905 
toward the eosinophil lineage (middle panel). After 14 days, the CLC/Gal-10 knock-906 
down cells display a significant reduction in the number of Fast Green stained 907 
secondary granules (middle panel), and cells stained on day 21 show increasing 908 
differences in cellular morphology as compared to control cells (bottom panel), with 909 
large empty granules (arrow). (B) Representative images of Fast Green/ Neutral Red 910 
stained cells 21 days post transduction. Cells transduced with CLC/Gal-10 specific 911 
shRNA manifest predominantly with large, empty granules. Images are representative 912 
of 2 independent experiments performed in triplicate. Size bars represent 5 µm. 913 
 914 
Figure 6. CLC/Gal-10 deficient (knock-down) eosinophils have fewer secondary 915 
granules, a non-proliferative phenotype, decreased MBP-1 expression, and 916 
increased secretion of EDN in response to PAF stimulation. (A) CLC/Gal-10 knock-917 
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down cells display an ~42% decrease in average number of secondary granules as 918 
compared to non-target shRNA transduced cells. (B) Cell populations transduced with 919 
CLC/Gal-10 shRNA show a dramatic increase of cells with no detectable granules and a 920 
strikingly smaller number of cells with more than 15 granules. (C) CLC-deficient cells 921 
display a non-proliferative phenotype, in contrast to non-target shRNA treated cells that 922 
continued to proliferate throughout the 21 days, although at a slower pace than 923 
untreated cells (expected being under Puromycin selection). (D) CLC/Gal-10 knock-924 
down causes a significant decrease in ELISA detected levels of CLC/Gal-10 and MBP-1 925 
in cell lysates, but no significant change in EDN, ECP, and EPX expression. CLC-926 
deficient eosinophils still exhibit dose-dependent secretion of EDN (E) and EPX (F) 927 
when activated with the secretagogue PAF. The secretion of EPX (F) by CLC-deficient 928 
eosinophils was not significantly different from untreated or non-target shRNA control 929 
cells; however, amounts of secreted EDN (E) was significantly higher in CLC-deficient 930 
eosinophils. Results represent mean (200 counted cells per treatment group) ± SEM 931 
from 2 independent experiments. (ns = not significant,**p ≤ 0.01, ***p ≤ 0.001,****p ≤ 932 
0.0001). 933 
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Online Repository Materials 
Materials and Methods 
Affinity purification of Rabbit IgG antibodies to CLC/Gal-10 
Rabbit IgG antibodies to crystal-derived eosinophil CLC protein were affinity-purified on 
a solid-phase CLC-Sepharose 4B column as previously described.1 In brief, a solid-
phased CLC column was first prepared using CLC protein isolated by crystallization from 
human eosinophil whole cell lysates; the CLC protein preparation contained a single 
homogeneous band on overloaded, silver-stained SDS-PAGE gels. The resolubilized, 
crystal-derived CLC protein was solid-phased to CNBr-activated Sepharose 4B resin 
using standard methodology.  
Co-Immunoprecipitation of CLC/Gal-10 and EDN 
Two different types of co-immunoprecipitations were performed to analyze the CLC/Gal-
10-EDN/ECP interaction.  First, blood eosinophil whole cell lysate was pre-cleared with 
100l (50% V/V) of protein A-Sepharose beads (Amersham Biosciences).  The 
supernatant was then incubated with anti-CLC/Gal-10 rabbit IgG antibody for one hour 
on ice, followed by the addition of the protein A-Sepharose beads. After a second 1-hour 
incubation, the beads were boiled in SDS-PAGE sample loading buffer, and the 
supernatant analyzed by Western blotting using antibodies to CLC/Gal-10 and EDN. 
Second, AML14.3D10 cells were lysed on ice in RIPA buffer (Santa Cruz) containing 
protease inhibitors. The supernatant was used for immunoprecipitation following a pre-
clearing step with a 50 µl (50% V/V) of protein G-Sepharose beads (Amersham 
Repository Text
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Biosciences) for two hours.  The supernatant was incubated with 0.4 µg anti-CLC/gal-10 
rabbit IgG antibody, 2 µg anti-EDN monoclonal antibody, or the appropriate non-immune 
rabbit IgG or mouse IgG control for 12 hours at 4°C.  This was followed by the addition of 
protein G beads for 2 hours.  The beads were collected and boiled in SDS-PAGE loading 
buffer for Western blotting.  
Affinity co-purification of CLC/Gal-10 and EDN 
Native CLC/Gal-10 was purified from eosinophils using a CLC/Gal-10 affinity-purified anti-
CLC antibody affinity column as described previously.1 For assessment of the effects of 
native CLC/Gal-10 protein on the RNase activity of purified EDN and ECP, CLC/Gal-10 
was purified with or without mild reduction (5 mM -mercaptoethanol) using the same 
affinity column. 
Ribonuclease enzyme activity assay 
For this assay,  the green fluorescence emitted from a cleavable fluoro-labeled substrate 
(Ambion, Austin, TX) was measured as relative fluorescence units on a Fluorocount 
Microplate Fluorometer (PerkinElmer, Meriden, CT). Briefly, 80 pg of purified native EDN 
was mixed with different amounts of crystal-derived CLC/Gal-10 protein (0, 40, 80, 400, 
800 and 1600 pg) or human placental ribonuclease inhibitor (New England Biolabs, 
Ipswich, MA) (0, 0.008, 0.04, 0.2, 1, or 5 units) in the presence of 5 mM DTT.  After a 1-
hr incubation at 4ºC, RNase substrate was added to each reaction mix and incubated for 
another 30 min at 37ºC before measuring relative fluorescence. 
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Confocal immunofluorescence microscopy  
Cytocentrifuge slides were prepared using a Cytospin-2 cytocentrifuge (Shandon, UK) at 
800 rpm for 2 minutes.  Slides were fixed for 10 minutes in 0.4% parabenzoquinone 
(Sigma-Aldrich), and permeabilizated for 8 min with n-octyl-β-D-glucopyranoside (Sigma-
Aldrich).2 Slides were blocked with 1.5% normal goat serum (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA), and probed with either monoclonal anti-CLC/Gal-10 
IgG antibody (Diaclone, Stamford, CT), mouse anti-EDN monoclonal antibody (11 µg/ml), 
or CD63 monoclonal antibody (1 µg/ml) (BD Biosciences). Non-immune rabbit and mouse 
IgG (Jackson ImmunoResearch Labs) were tested at the same concentrations as the 
antibody isotype negative controls. Detection was performed with Alexa Fluor 488-labeled 
goat-anti-rabbit IgG (Invitrogen Molecular Probes), Texas Red-labeled goat-anti-mouse 
IgG (Jackson ImmunoResearch Labs), or Alexa Fluor 568 goat anti-mouse IgG 
(Invitrogen Molecular Probes).  Images of immunofluorescent stained eosinophils were 
acquired using a Carl Zeiss 510 LSM equipped with a 63X oil immersion Plan-
Apochromat objective.   
Quantitative colocalization analysis was performed on images acquired using a 100X oil 
immersion objective. Single cells were selected as regions of interest (n=40 per treatment 
group) and mean colocalization coefficients were calculated by Pearson’s correlation 
method. Data is presented as mean ± SEM. Statistical analysis was performed using 
GraphPad Prism software (GraphPad, San Diego, CA) by two-way analysis of variance 
(ANOVA), followed by Tukey post hoc analysis. 
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Glycan microarray 
High-throughput glycan microarray screening was performed in collaboration with the 
NIH-funded Consortium for Functional Glycomics (CFG) according to their standard 
protocol (Protein-Glycan Interaction Core (H), Emory University School of Medicine, 
Atlanta, GA). Purified protein and primary antibodies were provided to the CFG for 
screening. The primary antibodies used include the affinity-purified rabbit polyclonal anti-
CLC/Gal-10 antibody (described in the manuscript), a monoclonal antibody to the FLAG-
peptide (Sigma- Aldrich), and a monoclonal antibody to FLAG-FITC (Sigma-Aldrich). A 
number of screening strategies were used for three different attempts at CLC/Gal-10 
ligand identification. These included: (1) Screening of crystal-derived CLC/Gal-10 purified 
from AML14.3D10 eosinophils an detection with purified polyclonal anti- CLC/Gal-10 
antibody, (2) screening of recombinant CLC/Gal-10 with a C-terminal FLAG sequence 
(rCLC/Gal-10-FLAG) and detection with either anti-FLAG or anti-FLAG-FITC monoclonal 
antibodies, (3) screening of crystal-derived CLC/Gal-10 directly labeled with FITC, and 
(4) screening of the recombinant quintuple mutant of CLC/Gal-10 (rQM-CLC/Gal-10-
FLAG) which contains a consensus galectin CRD (Q55N, C57R, R61T, Q75E, E77R) and 
detection with FITC- conjugated anti-FLAG antibody.  
The first screening attempt utilized a microplate array (Plate version 3.0 containing 205 
mammalian glycan targets), 3 while the subsequent samples were screen printed on 
microarrays (Printed microarray version 3.0 containing 285 mammalian glycan targets).4 
Modeling molecular interaction of CLC/Gal-10 with EDN and ECP 
The atomic coordinates of EDN (PDB: 2BZZ), ECP (PDB: 1H1H), and CLC (PDB: 1LCL) 
obtained from the Protein Data Bank were used for analysis. To account for CLC/Gal-10 
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dimers observed in solution, a CLC/Gal-10 possible dimer was modelled using Gal-1 as 
a template. A homology model was built for mEAR1 using EDN (PDB: 2BZZ) as a 
template. Structure based sequence alignments were carried out on FASTA format 
protein sequences of EDN (Uniprot reference number P10153), ECP (Uniprot reference 
number P12724), mEAR1 (GI number 32441901) and galectins- 1, 2, 3, 4, 7, 8, 9, 10 and 
13 (GI numbers are: Gal1 – 56554348, Gal2 – 119580571, Gal3 – 157829667, Gal4 – 
159163551, Gal7 – 3891480, Gal8 – 187609173, Gal9 – 219109219, Gal10 – 547870, 
Gal13 – 119577314). Only the mature polypeptide chain was taken for analysis. 
The PyMOL Molecular Graphics System (Schrödinger, LLC) was used to visualize and 
produce figures and to calculate the surface charge potential on molecules. Swiss-Model 
(http://swissmodel.expasy.org) online server was used to build homology models and the 
ClustalW server from http://ebi.ac.uk was used to align the sequences.5  Aline 
(http://crystal.bcs.uwa.edu.au/px/charlie/software/aline/) was used to edit the aligned 
sequences.6 SHARP2 (http://www.bioinformatics.sussex.ac.uk/SHARP2/sharp2.html) 
was used to predict possible protein interaction sites on surface of protein structures.7  
Results 
Glycan microarray 
The results of all glycan microarray screenings are summarized in Table S1.The use of 
either array format (Plate version 3.0 or Printed version 2.0) did not yield any high affinity 
binding partners for CLC/Gal-10. rCLC/Gal-10-FLAG showed some affinity for glycans 63 
(6-Su-GalNAcα -Sp2 or α-N-acetyl-D-galactosamine-6-sulfate) and 147 (Neu5Acα2-
3GalNeu5Aca2-3GalNAcα-PAA-Sp2 or GM4) on the version 3.0 plate array, but gave no 
results when tested on the version 2.0 printed array.  
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Table S1. Glycan microarray screens 
Protein Array Results Comment 
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3GalNAcα-Sp8 
 










More rigorous washing of the plate resulted in dissociation of the bound CLC/Gal-10, 
suggesting non-specific and/or low-affinity interactions with these targets. Our 
collaborators at the CFG did not believe these interactions to be meaningful given the 
great variations between replicates (high coefficient of variation (CV). In addition, glycan 
147 is a multivalent ligand that is not a typical galectin ligand. Similar low affinity and non-
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specific interactions with atypical galectin ligands were observed for the recombinant 
quintuple mutant of CLC/Gal-10 (rQM-CLC/Gal-10-FLAG). 
Molecular modelling of CLC/Gal-10 interactions with EDN and ECP 
Based on the available 3D structures of EDN (PDB: 2BZZ) and ECP (PDB: 1H1H) their 
surface charges were determined to be very different, as seen in Figure S1 and S2. The 
homology model of mEAR1 exhibits similar surface charge distribution as EDN (Fig. S1).  
 
Figure S1. Surface charge potential representation of EDN, ECP and mEAR1. EDN and 
mEAR1 exhibit similar surface charge compared to ECP. 
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Figure S2. Multiple sequence alignment of EDN, ECP and mEAR1. Residues that belong 
to the hydrophobic patch (highlighted in yellow) and positively charged residues 
(highlighted in cyan) of EDN and corresponding residues in ECP and mEAR1 are shown. 
Residues highlighted in red are different in terms of their property when compared to 
EDN. The residue highlighted in green is the mannosylated tryptophan of EDN. 
To confirm our observation, we used SHARP7 to identify possible residues that would be 
involved in protein-protein interactions between EDN and CLC/Gal-10. The results are 
shown as cartoon figures S3 (for EDN) and S4 (for CLC/Gal-10). Residues as identified 
by SHARP are listed below for EDN, CLC/Gal-10 and mEAR1: 
EDN: L45, T46, S76, Q77, V78, P79, I81, H82, T101, P102, A103, N104, M105, F106, 
I133, I134 
CLC/Gal-10: S2, L3, L4, P5, V6, P7, Y8, T9, P26, L27, V28, C29, L31, N32, E33, Y35, 
H53, Q55, R60, R61, Q125, W127, R128, D129, S131, F135 
mEAR1: T46, H29, T50, N54, V58, C59, C66, H75, N76, S78, S79, R80, V81, H82, V85, 
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R104, S105, L106, E107, Y108, T110, L131, D132, G133, T134, F135 
 
Figure S3. (A) Cartoon representation of EDN with hydrophobic residue rich region 
(yellow) (with some electro-negative charge) and positively charged residues (purple) 
shown as ball-and-stick model. (B) Hydrophobic residue rich region as calculated by 
SHARP2 on the surface of EDN that might be involved in protein-protein interactions. The 
total surface area covered by this patch is ~39 Å3 which is equivalent to the similar surface 
patch observed on CLC/Gal-10 (~39 Å3). 
 
A                                                                         B
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Figure S4. (A) Complementary surface patch with hydrophobic residues and electro-
positive charge on CLC/Gal-10 that is predicted to exhibit interaction with EDN. (B) 
SHARP predicted residues are shown as ball-and-stick model. 
  
A                                                                         B 
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Determination of protein purity by SDS-PAGE 
In order to estimate the purity of protein preparations, we analyzed the purified proteins 
by SDS-PAGE (Figure S5). Both CLC/Gal-10, derived by crystal solubilization, and EDN 
were shown to be of high purity. 
Figure S5. SDS-PAGE of CLC/Gal-10 and EDN shows purity of protein preparations. 
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CLC/Gal-10 shRNA knock-down in western blot 
Figure S6. Analysis of cell lysates 14 days after CLC/Gal-10 shRNA knock-down in 
CD34+ hematopoietic progenitors induced to differentiate into eosinophils by IL-5  
demonstrates their complete lack of CLC/Gal-10 expression by western blotting 
compared to untreated, vector and non-target shRNA control cells. Immunoblotting for 
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Quantitation of colocalization between CLC/Gal-10 and EDN/CD63 
Figure S7A. Pearson’s correlation coefficients for CLC/Gal-10 and EDN colocalization 
without (control) or with  IFN- (500 U/ml) activation of human peripheral blood eosinophils 
at 10 and 30 minutes. 
Figure S7B. Pearson’s correlation coefficients for CLC/Gal-10 and CD63 colocalization 
following activation of human peripheral blood eosinophils with IFN- (500 U/ml) for 2, 10, 
30, and 60 min. 
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